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Abstract
This study aimed to characterize genetic features of HIV-1 subtype C envelope glycoproteins capable of eliciting cross-reactive neutralizing
antibodies during natural infections. The gp160 sequences were determined for 36HIV-1 subtype C isolates (donor viruses) from infected individuals
residing inMalawi, Zimbabwe, Zambia and South Africa, whose sera displayed a range of cross-neutralizing activities against a panel of 5 subtype C
and 5 subtype B viruses (panel viruses). Hierarchical clustering analysis of neutralization data of the panel viruses predicted phylogenetic
relationships between subtype B and C panel viruses, suggesting some subtype-specific neutralization determinants. A similar comparison of subtype
C donor viruses showed no significant correlation; however of three donor sequence pairs resolvable by phylogenetic analysis, two were also
associated within the neutralization clustering dendrogram, suggesting that closely related viruses may elicit antibodies targeting common
neutralization determinants. Significantly, viruses that had shorter V1–V4 loops induced antibodies that showed more neutralization breadth against
the subtype C panel viruses (p=0.0135). This study indicates that that some structural features of envelope, such as shorter variable loops, may
facilitate the elicitation of cross-reactive neutralizing antibodies in natural infections. Collectively these data provide some insights into design
features of an envelope immunogen aimed at inducing neutralizing antibodies.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1 subtype C; Neutralizing antibodies; EnvelopeIntroduction
The HIV-1 epidemic has continued to expand with an
estimated 39.5 million people worldwide now infected
(UNAIDS/WHO, 2006) making a preventative vaccine an
urgent global health priority. It is widely believed that such a
vaccine would require the induction of both virus-specific CD8+
T cells and neutralizing antibodies (nAbs) (Letvin et al., 2002;
Mascola, 2003). Evidence for the role of nAbs comes from
studies with non-human primates which have confirmed the
protective capacity of passively transferred nAbs (Baba et al.,⁎ Corresponding author. Fax: +2711 386 6453.
E-mail address: pennym@nicd.ac.za (P.L. Moore).
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doi:10.1016/j.virol.2007.06.0132000; Hofmann-Lehmann et al., 2001; Mascola et al., 1999,
2000; Parren et al., 2001; Veazey et al., 2003) and from recent
data showing that, in some HIV-infected individuals, mono-
clonal nAbs can reduce the rate of viral rebound following a
structured treatment interruption (Trkola et al., 2005).
Despite considerable effort, there has been little progress in
creating a vaccine capable of eliciting nAbs, most likely due to
difficulties in designing an immunogen that sufficiently re-
sembles the native Env trimer (Garber et al., 2004). Immunogen
design is hampered by Env variable loops which sterically shield
critical epitopes. In addition, an “evolving glycan shield” and the
occlusion of neutralizing antibody sites by oligomerization
present further challenges (Garber et al., 2004; Wei et al., 2003).
High envelope sequence diversity may also diminish the ability
of a vaccine to induce broadly cross-reactive antibodies.
Fig. 1. Maximum likelihood phylogenetic trees indicating the Env amino acid
sequence relationships between: (A) donor viruses; (B) panel viruses. Numbers
associated with branches represent the percentage of 100 nonparametric
bootstrap datasets supporting their existence. Branches with less than 50%
support have been collapsed to clarify the mostly unresolved star-like nature of
the subtype C virus phylogenies. Arrows indicate well supported relationships
between sequence pairs that also cluster closely together in the neutralization
dendrogram.
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ted regional serotypes, with sera from South Africa preferen-
tially neutralizing subtype C isolates from South Africa
compared to those from Malawi, there are extensive data
which demonstrate cross-neutralization between subtypes. This
suggests that there may be neutralization determinants common
to different HIV-1 subtypes (Kostrikis et al., 1996; Moore et al.,
1996; Nyambi et al., 1996; Weber et al., 1996).
To design an effective Env subunit vaccine, further data are
needed to determine which portions of Env are most useful for
inclusion in a vaccine immunogen. While there are many
studies investigating the neutralization properties of serum
(Gray et al., 2007; Li et al., 2006a; Richman et al., 2003; Wei et
al., 2003) and the identification of neutralization epitopes
(Binley et al., 2004; Gray et al., 2006; Zwick et al., 2005), only
a few studies have investigated the properties of viruses in
natural infections which are associated with the induction of
these antibodies (Li et al., 2006b). To identify the genetic
characteristics of HIV-1 subtype C envelopes capable of
eliciting broadly cross-reactive nAbs, we analyzed gp160
sequences from 36 HIV-1 subtype C infected individuals for
whom neutralization data from matched serum samples were
available. Our data indicate that there is a limited correlation
between the phylogenetic relatedness of viruses and the cross-
reactivity of the nAbs they induce. Also we show that some
structural features of envelope, such as shorter variable loops,
may facilitate the elicitation of cross-reactive nAbs in natural
infections.
Results
The HIVNET 028 study is a natural history study that was
conducted to evaluate immune responses to HIV-1 subtype C
infection (Gray et al., 2005). Serum from individuals residing in
Malawi, Zambia, Zimbabwe and South Africa was previously
used to examine nAb responses against a panel of five subtype C
and five subtype B viruses (referred to hereafter as panel viruses)
(Taylor et al., paper in preparation). There was extensive cross-
neutralization of the subtype B and C panel viruses by subtype C
sera suggesting common neutralization epitopes between sub-
types: the average percentage of sera neutralizing each of the
subtype C panel isolates was 56% compared to an average of
57% for the subtype B panel isolates. The gp160 region from 36
of these individuals was sequenced (referred to hereafter as
donor viruses) using plasma samples collected at the same time
point as serum samples used in the neutralization assays. All
donor virus nucleotide sequences grouped with reference
subtype C sequences with no evidence of inter-subtype re-
combination (results not shown). A maximum likelihood
phylogenetic tree constructed using amino acid sequence data
from donor viruses indicated potentially significant clustering
(an excess of 50% bootstrap support) of only three sequence
pairs (Fig. 1A). Although all three pairs were sampled from the
same geographical region, in general there was no clustering of
subtype C viruses based on their geographical origin. The
subtype B and C panel viruses clustered separately as expected
(Fig. 1B).Genetic properties of panel viruses
Since variable loop lengths and predicted N-glycosylation
(PNG) site numbers may impact neutralization sensitivity, we
compared these features of the 5 subtype B and 5 subtype C
panel virus sequences. There were no significant differences
between variable loop lengths and PNG numbers in the subtype
B and C panel virus sequences. However, the subtype C Env
proteins tended to have slightly shorter variable loops (median
174 C. Rademeyer et al. / Virology 368 (2007) 172–181V1–V2=63 aa and V1–V4=277 aa) and fewer predicted gly-
cosylation sites (median=29) compared to the subtype B pro-
teins (median V1–V2=67 aa, V1–V4=282 aa, and PNG=31).
We then looked at the relationship between variable loop
length, PNG number and neutralization sensitivity. There was a
significant inverse correlation between V1–V2 length in the
subtype C panel viruses and the median titer at which they were
neutralized (Spearman r=−0.7723, p=0.0126). There were,
however, no significant correlations between neutralization
sensitivity and either V1–V4 length or PNG number for both
subtypes. Since the subtype C viruses were not more sensitive to
neutralization than the subtype B panel viruses, the impact of the
shorter V1–V2 loop on the overall neutralization phenotype of
subtype C viruses is probably minimal.
Relationship between donor sequences and neutralized panel
viruses
We investigated whether the panel viruses were more easily
neutralized by antibodies elicited by viruses to which they were
genetically more closely related. To do this, the amino acid pair-
wise distances of the panel viruses were compared to those of
donor viruses which either did, or did not, induce a neutralizing
response. The overall median percentage amino acid pair-wise
distance between panel and donor virus sequences from
neutralizing sera was 16.4% (n=183) compared to 15.5%
(n=138) for sequences from sera that were unable to neutralizeFig. 2. Genetic relationship between subtype C and B panel viruses and subtype C
circles) with median amino acid pair-wise distance indicated by a horizontal line. Pane
the y-axis.panel viruses. The difference in percentage pair-wise distance
was higher for the subtype B panel [23% (n=85) for neutralizing
sera; 24% (n=59) for non-neutralizing sera] compared to the
subtype C panel [14% for both neutralizing (n=98) and non-
neutralizing (n=79) sera] as expected given that all donor
viruses were subtype C (Fig. 2). Donor viruses eliciting a
neutralizing response to three panel viruses (Mal-2-8, Du174
and QH0515) were more closely related to these panel viruses
than were donor viruses that did not induce a neutralizing
response. However, the opposite was found for six other panel
viruses. None of these differences was statistically significant.
Furthermore, no correlation was observed between the amino
acid pair-wise distance between panel and donor virus sequences
(for subtypes B and C separately) and the neutralization titers.
These data suggest that antibodies elicited by donor viruses are
not obviously more likely to neutralize viruses with which they
share the greatest genetic similarity, as measured by amino acid
pair-wise distances.
Hierarchical neutralization clustering
We used hierarchical neutralization clustering to classify the
capacity of donor sera to neutralize panel viruses (Fig. 3). Donor
sera with the most potent neutralizing activity are grouped in the
top half of the neutralization tree while sera with the least potent
activity are grouped in the bottom half of the tree. Similarly,
panel viruses that are most potently neutralized cluster on the leftsequences from neutralizing sera (black circles) and non-neutralizing sera (gray
l isolates are indicated along the x-axis and amino acid pair-wise distances along
Fig. 3. Hierarchical clustering of 36 donor sera and ten panel viruses according to ID80 neutralization potencies and susceptibilities, respectively. The dendrogram on
the left was constructed by clustering sera according to their neutralization capacity. Similarly, the dendrogram at the top was constructed by clustering panel viruses
according to their neutralization susceptibilities. This resulting two-dimensional clustering pattern was color-coded in order to clarify neutralization profiles. Arrows
indicate closely clustered sera that were induced by viruses that were significantly clustered by phylogenetic analysis of the gp160 amino acid sequence. Legends
indicate geographic origins and neutralization potencies. ND=not done.
175C. Rademeyer et al. / Virology 368 (2007) 172–181of the panel virus neutralization tree while those viruses least
potently neutralized cluster on the right of the tree.
We compared the topologies of the donor and panel virus
neutralization dendrograms with their corresponding gp160
amino acid sequences phylogenetic trees and found good
evidence that the panel virus neutralization tree (Fig. 3) more
closely resembles the phylogenetic tree (Fig. 1B) than would
have been expected by chance (p=0.034 using the permutation
test described in Materials and methods). This suggests that the
panel viruses contain some neutralization determinants that are
subtype-specific.
There was, however, no significant correspondence between
the neutralization clustering and phylogenetic relationships of
donor viruses (p=0.584). Despite this it is noteworthy that of
three sequence pairs grouping together in the mostly star-like
donor virus gp160 tree, two of these pairs also clustered closely
in the neutralization tree (black and gray arrows in Figs. 1Aand 3). It is possible, therefore, that the gp160 sequences of
these two pairs of viruses have common genetically determined
immunogenic features.
There are three likely reasons why we observed concor-
dance between the neutralization clustering and phylogenetic
trees of panel viruses but find no concordance between the
trees for the donor viruses: (1) the panel viruses are more
diverse and yield a phylogenetic tree which distinguishes
between subtype B and C and resolves some clusters (with
bootstrap values N80%) within subtype B, whereas all donor
viruses are subtype C and these yield a very poorly resolved
phylogenetic tree; (2) the neutralization clustering dendrogram
for the panel viruses is based on up to 36 informative characters
whereas the dendrogram for the donor viruses is based on at
most ten informative characters; (3) the ongoing evolution of
plasma virus means that the contemporaneous virus (sequenced
here) may differ from the virus which elicited the nAbs.
Fig. 4. (A) V1–V2 or (B) V1–V4 amino acid length of donor sequences
analyzed according to whether the corresponding serum sample neutralized
(black circles) or did not neutralize (gray circles) each of the panel viruses. The
median length is indicated by a horizontal line. Collective statistical analysis for
subtype C and B isolates is shown below the x-axis. Asterisk indicates pb0.05.
176 C. Rademeyer et al. / Virology 368 (2007) 172–181Although there will be considerably less envelope variation
within an individual over this period of time compared to the
extent of variation between individuals, the relationship
between donor serum neutralization and the phylogenetic tree
of the donor virus may be somewhat weakened as a result.
Given more panel viruses and a more diverse set of donor
viruses, it is possible that concordance between donor virus
neutralization and phylogenetic trees could be detectable.
Relationship of donor virus loop length and number of PNGS
with neutralizing antibody responses
We investigated whether the length of the V1–V2 and V1–
V4 regions of donor viruses affected the antibody responses they
elicited. A comparison of V1–V2 loop lengths of donor viruses
that induced nAbs, with those of donor viruses that did not
induce nAbs, indicated that eight of the ten panel viruses were
neutralized more efficiently with sera induced by donor viruses
that had shorter loop lengths. This trend was, however, not
statistically significant when each panel virus was analyzed
separately (Fig. 4A). However, when donor virus sequences
were analyzed collectively, the V1–V2 lengths of viruses
inducing neutralizing sera against subtype C panel viruses were
significantly shorter (median, 65.5 amino acids) than those from
donor viruses inducing non-neutralizing sera (median, 69 amino
acids, p=0.0296; Fig. 4A). While there was a similar trend for
shorter V1–V2 sequences of donor viruses to induce more
potently neutralizing sera against subtype B panel viruses, this
was not significant (p=0.6593).
A similar trend was observed when the entire V1–V4 region
was analyzed. It was found that neutralization of eight of the ten
panel viruses was better mediated by sera induced by donor
viruses with shorter V1–V4 regions (Fig. 4B). This trend was
significant for two panel viruses [Mal-2-8 (p=0.04) and
QH0515 (p=0.0153)]. When subtype C data were analyzed
collectively, the V1–V4 amino lengths of donor viruses
inducing neutralizing sera were also significantly shorter
(median, 276 amino acids) than those from donor viruses that
failed to induce neutralizing sera (median, 282 amino acids,
p=0.0135). Similar to the V1–V2 analysis, there was no
statistically significant association between V1–V4 length and
the ability of donor viruses to induce neutralizing sera against
subtype B panel viruses (p=0.4164).
We also examined the relationship between the number of
PNGs in the donor viruses and the neutralization capacity of the
sera they induced. The number of PNGs per sequence was
analyzed with respect to neutralization capacity for each serum
versus the panel viruses. With the exception of sera which
neutralized panel virus Mal-2-8, and independent of the panel
virus subtype, no significant differences were observed in the
number of PNGs in donor virus sequences that induced sera
which neutralized panel viruses versus those donor viruses that
failed to induce neutralizing sera. This was true whether we
analyzed either the number of PNGs over the entire gp160
region or only those within the V1–V4 or V1–V2 regions.
Donor virus sequences inducing sera that neutralized panel
virus Mal-2-8 had significantly reduced PNG numbers relativeto those predicted in donor sequences that did not induce sera
that neutralized Mal-2-8 (p=0.0444 over the entire gp160;
p=0.0349 over the V1–V4 region alone).
Discussion
This study aimed to characterize genetic features of HIV-1
subtype C envelope sequences capable of eliciting cross-
reactive nAbs in natural infection. Sequences were analyzed
from 36 individuals (from Malawi, Zimbabwe, Zambia and
South Africa) whose sera displayed a range of cross-neutraliz-
ing abilities against a panel of five subtype C and five subtype B
viruses. An important phylogenetic feature captured in the
hierarchical neutralization clustering dendrogram was the
division of subtype C and B panel viruses which provided
evidence that neutralization potency has some degree of
subtype specificity. Also, two pairs of closely related donor
viruses were identified in the phylogenetic tree that also clus-
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ing that closely related viruses in different people may elicit
antibodies targeting common neutralization determinants.
Finally, we provide evidence that viruses with shorter variable
loops in natural infections are more likely to induce cross-
reactive antibodies. This relationship was observed for neutra-
lization of subtype C but not subtype B panel viruses, further
supporting the existence of subtype-specific differences in
neutralization sensitivity.
The HIV-1 subtype C infected patients in this study, estimated
to have been infected for a median period of 17months (range 10
to 25 months), showed a broad range of abilities to cross-
neutralize both subtypes B and C panel viruses. However, a
significant inverse correlation was observed between the median
neutralization titer and the length of the V1–V2 region of the
subtype C panel viruses. This is similar to what has been
reported previously by Li et al. (2006a) who demonstrated an
inverse correlation between the length of the V1–V4 region and
neutralization susceptibility in HIV-1 subtype C infection. These
data contribute to a considerable body of evidence implicating
variable loops in (1) occlusion of antibody sensitive regions of
the viral envelope from monoclonal and plasma antibodies (Cao
et al., 1997; Cheng-Mayer et al., 1999; Ly and Stamatatos, 2000;
Pinter et al., 2004; Sagar et al., 2006), (2) neutralization escape
of subtype A and B viruses in vivo (Cao et al., 1997; Cheng-
Mayer et al., 1999; Ly and Stamatatos, 2000; Pinter et al., 2004;
Sagar et al., 2006; Wei et al., 2003), and (3) moderation of virus
neutralization sensitivity in subtypes A and C (Derdeyn et al.,
2004; Gray et al., 2007; Li et al., 2006a; Sagar et al., 2006). More
data on the antigenic targets of nAbs and the structural features
of HIV-1 envelopes from different genetic subtypes are needed
in order to clarify some of these findings.
It is well known that serum is more likely to neutralize
autologous virus from earlier time points (Gray et al., 2007;
Richman et al., 2003; Wei et al., 2003). However, viruses that
were genetically more similar to a panel virus were no more
likely to elicit antibodies able to neutralize it than viruses more
distantly related to it. This is not surprising given that this
method looks at primary Env sequences whereas epitopes are
influenced by both the tertiary structure of the envelope and the
quaternary nature of the trimer. To investigate this in more depth
we compared the topology of neutralization clustering and
phylogenetic trees constructed from the donor and panel virus
gp160 amino acid sequences. Although the donor virus
phylogenetic tree was highly unresolved, two pairs of sequences
clustered in both this and the neutralization tree, implying that
viruses with similar sequences might elicit similar nAbs in
different people. To explore concordance between phylogenetic
and neutralization clustering trees further, data would be needed
for both a more phylogenetically structured set of donor virus
sequences and a greater number of panel viruses. That such a
concordance may exist is evidenced by the fact that we have
found a definite association between panel virus genotype and
neutralization phenotype. With only one exception the neutra-
lization tree showed a reasonably clear split between panel
viruses of different subtypes, indicating that at least a fraction of
neutralization determinants are both specific to, and fairlycommon within, subtypes. Our data therefore add further
support to previous claims that South African subtype C viruses
have shared neutralization determinants (Bures et al., 2002).
Here we have extended that report to include subtype C viruses
circulating in Zambia and Zimbabwe.We suggest, therefore, that
some benefit may be derived from producing subtype C specific
Env based vaccines but also that the magnitude of this benefit
would probably not be overwhelming in that there is, for
example, clear evidence of cross-neutralization of subtype C and
B viruses in 28 of the 36 sera we have tested.
In vaccine studies, the Env variable loop lengths have been
implicated in determining the degree to which nAbs are elicited
(Srivastava et al., 2003). It has been proposed that Env proteins
with comparatively short variable loops might be responsible for
autologous neutralizing antibody titers in subtype C infected
individuals that are approximately 3.5-fold higher than those
seen in individuals infected with subtype B viruses which
generally express Env proteins with less compact loops (Li et al.,
2006a). We found that there was a relationship between the
neutralization capacity of sera and the variable loop lengths of
the viruses inducing the sera. Comparison of both the V1–V2
and V1–V4 lengths of donor viruses from neutralizing sera with
those from non-neutralizing sera showed that, in general, sera
which neutralized a particular panel virus had, on average,
shorter V1–V2 and V1–V4 regions than did viruses from sera
unable to neutralize the panel virus. Whereas this trend was
statistically significant for both the V1–V2 and V1–V4 lengths
when the subtype C panel viruses were analyzed collectively, it
was not significant for the subtype B panel viruses, which
suggests that there may be some inter-subtype differences in
neutralization determinants. These data suggest that polyclonal
sera elicited during natural infections in response to viruses with
shorter V1–V2 (and shorter V1–V4 region) lengths were in
general more effective at neutralizing our panel viruses. This
trend was independent of the variable loop (V1–V2 or V1–V4)
lengths of the individual panel viruses (data not shown).
Importantly, we could detect no significant influence of the
number of predicted PNGs in donor sequences on their
capacities to induce neutralizing sera. Reduced glycosylation
of the infecting virus in this study is therefore not linked to
elicitation of cross-reactive nAbs as has been suggested
(Pantophlet and Burton, 2006).
In conclusion, we found evidence for both an association
between the neutralization characteristics of viruses and their
phylogenetic relatedness, and the existence of subtype-specific
genetic neutralization determinants. However, sequences of
donor viruses associated with neutralizing sera were on the
whole not characterized by lower amino acid sequence identity
distances compared with sequences from non-neutralizing sera.
There was, however, evidence that viruses with shorter V1–V2
loops (and shorter V1–V4 regions) elicited antibodies that were
capable of more effectively neutralizing panel isolates. This
effect has been implied in other studies, but this is the first study
to demonstrate it in natural infections. These data therefore
provide further insights into necessary design features of an Env
based vaccine immunogen that is capable of effectively eliciting
broadly protective anti-HIV neutralizing antibody responses.
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Plasma and serum samples
Serum samples used in neutralization assays, and blood
plasma samples used to determine Env sequences, were
collected as part of the HIVNET 028 study from 36 HIV-1
positive individuals originating from four countries: Malawi
(MW, 525-prefix, n=5), Zimbabwe (ZW, 536-prefix, n=8),
Zambia (ZM, 541-prefix, n=10), and South Africa (ZA,; 615-
prefix for Durban samples, n=9; 616-prefix for Johannesburg
samples, n=4) (Table 1). Most individuals (89%) were females
and the group had a median age of 28. Individuals in this study
had median plasma viral loads of 1.6×104 genome copies ml−1
and correspondingly had relatively low CD4+ T cell counts
(median of 180 cells/μl). Date of infection was defined as the
midpoint between the last antibody negative ELISA date and the
first antibody positive ELISA. The median time from infection
was 17 months (range 10 to 25 months). Patient demographicTable 1
Clinical information for 36 HIV-1 positive donors
Origin Sample identifier Estimated months
post-infection a
Malawi 525-00016-0 15.0
525-00017-1 16.3
525-00030-1 NA
525-00031-6 NA
525-00032-7 12.2
Zimbabwe 536-00001-5 18.8
536-00008-0 12.0
536-00009-3 9.8
536-00010-7 14.9
536-00012-1 NA
536-00016-2 NA
536-00017-3 10.7
536-00020-5 13.7
Zambia 541-00003-6 25.2
541-00004-9 24.1
541-00006-2 22.6
541-00008-5 24.0
541-00009-8 24.6
541-00011-5 24.1
541-00013-1 22.8
541-00018-0 22.7
541-00019-3 21.5
541-00025-6 24.2
Durban, South Africa 615-00002-6 12.9
615-00004-4 15.8
615-00005-9 17.8
615-00007-8 21.1
615-00011-0 18.6
615-00032-5 14.1
615-00037-7 13.6
615-00038-1 13.6
615-00040-6 13.7
Johannesburg, South Africa 616-00009-1 NA
616-00046-1 NA
616-00048-6 NA
616-00050-3 NA
NA, not available.
a Estimated date of infection defined as midpoint between last antibody negativedata and clinical information were generated as part of the
HIVNET 028 study by co-investigators and are described in
Gray et al. (2005). Ethical approval for all samples was obtained
from institutional review boards of the University of the
Witwatersrand and the University of Cape Town, South Africa.
RT-PCR from blood plasma
RNA was extracted from blood plasma and cDNA of the
HIV-1 envgp160 was generated through reverse transcription
(Invitrogen Thermoscript™ RT-PCR System; GmbH, Karls-
ruhe, Germany). This was followed by a nested PCR reaction
using first-round primers G-f (5′-AAGCGGAGACAGCGAC-
GAAG-3′; HXB2 position 5981–6000) and envL-r (5′-AAGG-
CACCTGAGGTCTGACTGG-3′; HXB2 position 9001–9022)
using Expand Long template PCR System (Roche Molecular
Biochemicals). Cycling conditions were as follows: 1 cycle of
94 °C for 2 min; 10 cycles of 94 °C for 10 s; 50 °C for 30 s and
68 °C for 2 min; 25 cycles of 94 °C for 15 s; 50 °C for 30 s; 68 °CAge Gender CD4 count
(cells/μl)
Viral load
(RNA copies/ml)
44 M 340 53140
28 M 253 68521
18 F 608 8583
36 F 460 5014
30 F 239 67003
24 F 193 25079
18–45 F 455 20439
29 F 528 201238
18–45 F 324 2936
27 F 610 15588
18–45 F 424 4160
28 F 167 46328
20 F 780 6189
NA F 149 15556
29 F 453 37706
18–45 F 250 3880
18–45 F 136 115968
18–45 M 318 5668
18–45 F 360 26329
22 F 326 9533
30 F 216 25249
18–45 F 476 93697
33 M 256 14089
18–45 F NA 46984
36 F 522 14199
18–45 F 600 6841
18–45 F 345 5726
25 F 448 8048
NA F 255 16952
NA F 32 177259
44 F 592 2349
28 F 180 385188
NA F 371 15565
NA NA 45 202735
NA F 538 NA
NA F 384 9639
and first antibody positive ELISA.
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cycle had a 68 °C extension step for 7 min. Second round
reactions were performed using envFf (5′-TCATAGCAA-
TAGTTGTGTGG-3′; position 6111–6130) and envKr (5′-
CTTATAGCAGGCCATCC-3′; position 8830–8846) generat-
ing a 2736 bp envFK fragment. Reactions (50 μl) used ExSel
High Fidelity DNA Polymerase (JMR Holdings, Sevenoaks,
UK) with 1× reaction buffer, 0.2 mM of each dNTP, 5 pmol of
each primer and 0.625U ExSel taq. PCR cycling conditions used
for this second round were identical except that annealing
temperature was increased to 55 °C.
Where amplification of this fragment failed, five smaller
overlapping fragments were generated using primers EnvAf (5′-
GAAAGAGCAGAAGACAGTGGC-3′; position 6203–6223)
and envEr (5′-TTAGAATCGCATAACCAG-3′; position 6886–
6903) for an envAE fragment (702 bp); envBf (5′-TAACA-
CAAGCCTGTCCAAAGGT-3′; position 6826–6847) and
envBr (5′-AATTTCTAGGTCCCCTCCTGA-3′; position
7317–7337) for an envB fragment (512 bp); envDf (5′-AGCA-
CATTGTAACATTAGT-3′; position 7208–7226) and envAr
(5′-TGCTGCTCCCAAGAACCCAA-3′; position 7783–7802)
for an envDA fragment (594 bp); envMf (5′-GAGGAGATAT-
GAGGGACAATTGG-3′; position 7638–7661) and envNr
(5′-GGTGAGTATCCCTGCCTAACTCTA-3′; position 8342–
8365) for an envMN fragment (727 bp); envNf (5′-TGACCTG-
GATGCAGTGG-3′; position 8101–8117) and envKr (5′-CTTA-
TAGCAGGCCATCC-3′; position 8846–8830) for an envNK
fragment (745 bp). These 50 μl reactions were performed using
Supertherm DNA polymerase (JMR Holdings, Sevenoaks, UK)
with 1× reaction buffer, 2 mM MgCl2, 0.2 mM of each dNTP,
5 pmol of each primer and 0.625USuperthermDNApolymerase.
PCR cycling conditions used for these fragments were 1 cycle of
94 °C for 2 min, 30 cycles of 94 °C for 15 s, 55 °C for 30 s, and
72 °C for 30 s with a final extension step at 72 °C for 7 min.
Sequencing and sequence analysis
DNA amplicons were purified by QIAquick PCR Purifica-
tion Kit (Qiagen, Valencia CA, USA). Both strands were
sequenced directly with five pairs of second-round overlapping
primers using the ABI PRISM® BigDye™ terminator V3.0
Cycle sequencing Ready reaction Kit and an ABI PRISM™
3100 Genetic Analyser (Applied Biosystems, Warrington, UK).
Nucleotide sequences were edited using ChromasPro V.1.11
(www.technelysium.com.au/ChromasPro.html) and aligned and
translated using BioEdit version 5.0.2 (http://www.mbio.ncsu.
edu/BioEdit/bioedit.html) (Hall, 1999). Phylogenetic related-
ness of sequences was inferred by maximum likelihood (JTT
model, 100 full maximum likelihood nonparametric bootstrap
replicates) using PhyML (Guindon and Gascuel, 2003).
Amino acid distance analysis was performedwith uncorrected
(Hamming) distances calculated in MEGA version 2.1. Per-
centage nucleotide diversity was determined using the Kimura 2-
parametermodel. The number of potential N-linked glycosylation
(PNG) sites was determined using the program N-glycosite
(http://www.hiv.lanl.gov/content/hiv-db/GLYCOSITE/glycosite.
html).Neutralization assays
Serum samples from 36 individuals were tested in PBMC
neutralization assays against a panel of 10 primary viruses. This
included Du151, the South African subtype C prototype vaccine
strain (isolated 2 months after infection), and Du174 (isolated 14
months after infection) both from Durban, South Africa
(Williamson et al., 2003); a Malawian isolate (Mal-2-8); a
Zimbabwean isolate (Zim-10-7); and a Zambian isolate (Zam-
21-7). These latter 3 subtype C viruses were isolated from stored
HIVNET 028 PBMC collected within 6 months of infection,
except for the Zambian isolate where exact date of infection was
not known. The remaining five viruses were subtype B isolates:
one obtained within 2 months of infection from a male residing
in the USA (6101); one from an male living in Trinidad who was
estimated to have been infected 1 month earlier (QH0515) (Li
et al., 2005); two from individuals in South Africa undergoing
seroconversion illness (SM1 and SM2); and one from a South
African AIDS patient, DS8. Subtype C viruses and one of the
subtype B viruses (QH0515) were from heterosexual transmis-
sions and the subtype B viruses were from homosexual
transmissions. All HIV-1 isolates utilized the CCR5 co-receptor
(NSI phenotype), except for DS8 which used CXCR4 (SI
phenotype). A total of 177 neutralization assays were done using
the 5 subtype C viruses (3 not done due to limited serum
quantities) and 144 assays (37 not done) using the subtype B
panel viruses. Neutralization titers were calculated as the reci-
procal of the serum dilution that reduced p24 antigen production
by 80% relative to a negative control serum sample from anHIV-
negative donor (ID80) (Taylor et al., paper in preparation).
Hierarchical neutralization clustering
Dendrograms grouping sera and viruses based on the
similarity of either their neutralization susceptibility (for panel
viruses) or their ability to neutralize panel viruses (for donor
viruses) were generated using the Mcquitty agglomeration
method implemented in R (The R Foundation for Statistical
Computation version 2.0.1, 2004) (Ihaka and Gentleman, 1996).
This method has previously been applied by Binley et al. (2004)
to classify viruses into immunotypes. Actual ID80 neutralization
titers were used in generating dendrograms. Neutralization
potency was visualized by categorizing neutralization titers into
five color-coded groups: (1) samples with no detectable
neutralization (titers of b1:4), (2) samples with titers of N1:4
to b1:12, (3) samples with titers of N1:12 to b1:36, (4) samples
with titers of N1:36 to b1:108 and (5) samples with titers of
N1:108 indicating highly effective neutralization.
Statistical analyses
Nonparametric regression analyses (Spearman's Rank) were
carried out using GraphPad Prism 4.0. Correlations were
considered statistically significant when p values were smaller
than or equal to 0.05. Evidence of correlation between neutrali-
zation clustering and phylogenetic relatedness of Env amino
acid sequences was examined using a permutation test. The
180 C. Rademeyer et al. / Virology 368 (2007) 172–181maximum likelihood tree of the Env amino acid sequences and
an enforced topology corresponding to that of the inferred
neutralization clustering dendrogram was determined using
PhyML (JTT model; Guindon and Gascuel, 2003). The
likelihood of this tree was then compared to those of 1000
trees constructed using datasets in which the identities of Env
sequences had been randomly shuffled. The probability of the
neutralization clustering dendrogram topology containing sig-
nificantly more phylogenetic information than could be
accounted for by chance corresponded to the proportion of
randomized datasets that yielded a higher likelihood estimate
than the actual dataset.
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